Technology Enhanced Nurse Navigator Trial (TENN Trial) (TENN)
16. april 2015 oppdatert av: Mercy Medical Center
Technology Enhanced Nurse Navigator Trial (TENN Trial) Phase III Randomized Controlled Trial
The purpose of the Technology Enhanced Nurse Navigator Trial (TENN) Trial is to find the best way to provide breast cancer patients with information through a computer connected to the internet.
The study will determine if giving information during treatment may help patients cope better with their treatment.
The hypothesis is that participants assigned to receive Technology-Enhanced Nurse-directed Navigation will be more likely to adhere to treatment regimens and have improved symptom management than women who have access to the education portal only.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Treatment for breast cancer has been proven to decrease death from breast cancer.
The key to the success of treatment is getting the right dose at the right time, but many women do not receive optimum treatment.
Treatment delays, missed appointments, and failure to take medication on a regular basis lead to poorer survival from breast cancer.
In a study among low income women only 60% of women adhered to the treatment, that is, taking their medication at least 80% of the time.
Twenty percent of women, who were supposed to take 5 years of hormone treatment, had stopped their medication in the first year.
Similar problems occur with chemotherapy and radiation therapy.
Many barriers interfere with adherence to treatment, including poor symptom management, missed appointments, and cancelled appointments.
Nurse navigation can help manage and minimize symptoms, assist with appointment reminders, and answer questions to obtain optimum breast cancer treatment.
The goal of the proposed study is to rigorously test the delivery of nurse-navigation through a web-based knowledge and communication portal (Technology Enhanced Nurse-directed Navigation (TENN) for its impact on treatment adherence and symptom management.
The success of this program will be measured by improved treatment adherence, health outcome measures such as fatigue and symptom management, patient-reported quality of life, reduced distress, and patient satisfaction.
Studietype
Intervensjonell
Registrering (Faktiske)
101
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21202
- The Prevention and Research Center at Mercy Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Enrolled in the BCCDT program for the adjuvant treatment of breast cancer,currently on medical assistance,or with an income that does not exceed 300% of the Federal Poverty Level, based on family size.
- English-speaking
- Able to give informed consent
- Not enrolled in another case-management program
- Residing within the Verizon 3G Coverage area
Exclusion Criteria:
- Non-English speaking
- Enrolled in a case management program.
- Unable to sign an informed consent
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Interactive navigational support
Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
|
Interactive navigational support is provided by a nurse and social worker navigators
|
|
Aktiv komparator: control arm
Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
|
a netbook computer with internet access is provided to participants on the control arm.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment Adherence
Tidsramme: Baseline, 6 months and 12 months
|
Adherence will be determined by review of the claims data.
All claims, including hormone, chemotherapy and radiation therapy, doctor's visits, and hospitalizations, are sent through the BCCDT program.
For chemotherapy and radiation therapy, relative dose intensity (RDI) will be measured.
Adherence to hormone therapy will be measured as the medication possession ratio (MPR).A self-reported measure of adherence will be correlated with these more objective measures (Morisky et al. 1986).
|
Baseline, 6 months and 12 months
|
|
Fatigue
Tidsramme: Baseline, 6 months and 12 months
|
Fatigue will be measured using a visual analogue scale.
The FACT-B will be used to measure quality of life.
The FACT-B is the Functional Assessment of Cancer Therapy-Breast, a reliable and valid measure for assessing subjective health-related quality of life among breast cancer survivors (Brady et al. 1997).
The FACT-B includes both the FACT-General (FACT-G) and the Breast Cancer Subscale (BCS).
The FACT-B has shown high internal consistency with a Cronbach's alpha of 0.90 (Brady et al. 1997).
|
Baseline, 6 months and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient satisfaction
Tidsramme: Baseline, 6 months and 12 months
|
As recommended by the NCI Navigation Research Program, we will include the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) designed to measure self-efficacy and positive attitude for cancer patients (Wolf et al. 2005).
|
Baseline, 6 months and 12 months
|
|
Quality of life
Tidsramme: Baseline, 6 months and 12 months
|
As a measure of distress, we will use the Impact of Events scale revised (IES-R), an updated version of the original Impact of Events scale (IES) (Horowitz et al. 1979;Weiss et al. 1997).
The IES-R is a validated measure of responses to a stressful life event and addresses distress and intrusive thoughts consistent with responses to the DSM-IV diagnosis criteria of PTSD.
The IES-R is readily modified to address an event such as diagnosis of cancer or a chemotherapy-related adverse event
|
Baseline, 6 months and 12 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kathy Helzlsouer, M.D., M.H.S., The Prevention and Research Center at Mercy Medical Center
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. februar 2012
Primær fullføring (Faktiske)
1. februar 2015
Studiet fullført (Faktiske)
1. februar 2015
Datoer for studieregistrering
Først innsendt
8. mai 2012
Først innsendt som oppfylte QC-kriteriene
9. mai 2012
Først lagt ut (Anslag)
10. mai 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
17. april 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. april 2015
Sist bekreftet
1. januar 2015
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- MMC2011-001
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .